Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, involving the issuance of a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, support platform expansion, and create new revenue streams [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, enabling the creation of a Biotech Exchange platform [3] Financial Details - The second tranche follows an initial investment in September 2025, valued at approximately $8 million in Bitcoin [1] - Under the licensing agreement, Datavault will receive a nonrefundable upfront license fee of $2.5 million in four installments, totaling $10 million, and is eligible for sales milestone payments up to $2.55 billion [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company’s technology suite includes customizable AI and Machine Learning automation, detailed analytics, and marketing automation [9]

Core Insights - Datavault AI Inc. has granted an exclusive worldwide license to Scilex Holding Company for its AI-driven technology, aimed at creating a Biotech Exchange platform for secure tokenization and monetization of biotech assets [1][2][3] - The agreement highlights the potential to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, providing an alternative for companies to secure non-dilutive funding [3][4] - Datavault AI's robust intellectual property portfolio includes key patents that support the secure tokenization and exchange of sensitive genetic information [4][6] Licensing Agreement Details - Datavault AI will receive a non-refundable upfront license fee of $10 million, paid in four installments of $2.5 million each by Scilex [6][8] - Additionally, Datavault AI is eligible for sales milestone payments of up to $2.55 billion based on Scilex achieving certain sales milestones [7][8] Technology and Market Potential - The technology licensed to Scilex is expected to extend into a Pharmaceutical Exchange platform, potentially transforming the pharmaceutical industry [2] - The tokenization opportunity in the pharmaceutical sector is significant, with estimates suggesting a market size of $2.0 trillion for drug sales and diagnostics [3][4] Intellectual Property and Innovations - Datavault AI's intellectual property includes a pending patent for "Platform and Method for Tokenizing DNA Data," which establishes a secure framework for tokenizing genetic information [4][6] - The company has a comprehensive suite of issued and pending patents that support the Biotech Exchange, enabling secure data handling and monetization [4][6] Previous Collaborations and Technological Advancements - The licensing agreement builds on Datavault AI's previous collaborations, including work with Brookhaven National Laboratory on biofuel research [5] - Datavault AI's technology suite is customizable and includes AI and Machine Learning automation, third-party integration, and detailed analytics [9]

Core Viewpoint - Semnur Pharmaceuticals has successfully completed its business combination with Denali Capital Acquisition Corp, transitioning to a public company to enhance growth and address non-opioid pain management needs [1][2][3] Company Overview - Semnur Pharmaceuticals, Inc. is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies, particularly targeting moderate to severe chronic radicular pain/sciatica with its product candidate SP-102 (SEMDEXA™) [4][5] - The combined company will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" starting September 23, 2025 [2][7] Business Combination Details - The business combination was officially closed on September 22, 2025, allowing Semnur to access public capital markets for business growth [1][3] - Scilex Holding Company owns approximately 87.5% of Semnur's common stock post-business combination, indicating strong backing for the company's future endeavors [7] Leadership Statements - Henry Ji, Executive Chairperson of Semnur, emphasized the importance of public capital markets in enhancing business growth and fulfilling the company's mission [3] - Jaisim Shah, CEO of Semnur, expressed pride in the company's leadership in non-opioid therapeutics and the aim to accelerate access to these treatments through advancing clinical development and payer adoption [3] Product Development Focus - Semnur is advancing its second Phase 3 clinical development for SP-102, which is a novel gel formulation for epidural administration aimed at treating chronic radicular pain/sciatica [3][4] - The company is committed to increasing access to prescription non-opioid therapeutics and expanding its market presence [3]